Maria-Victoria Mateos, MD, PhD

María-Victoria Mateos, MD, PhD, discusses the future clinical development of ciltacabtagene autoleucel in multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.

María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.

María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the design of the ongoing phase 3 CANOVA trial in patients with relapsed/refractory t(11;14) multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the rationale for the posthoc analysis of the phase III ARROW study in multiple myeloma.

Maria-Victoria Mateos, MD, PhD, associate professor of medicine, and director of the Myeloma unit at the University Hospital of Salamanca in Spain, discusses the impact of performance status on the outcomes of patients with multiple myeloma in the phase III ARROW trial.

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.